Table 2.
Selected Drugs That Should Be Used With Caution in Subjects Receiving Boceprevir or Telaprevir Because of Altered Metabolism
| Drug Class | Examples | Potential Impact |
|---|---|---|
| CYP3A substrates | ||
| Antiarrhythmics | Amiodarone Digoxin Lidocaine Quinidine | Increased arrhythmia |
| Antidepressants | Escitalopram* | Decreased efficacy of antidepressant |
| Antidepressants | Desipramine Trazodone | Increased sedation, dry mouth |
| Azole antifungals | Itraconazole Ketoconazole Posaconazole | Increased vomiting, diarrhea, hypertension |
| Antigout agents | Colchicine | Increased diarrhea |
| Calcium channel blockers | Amlodipine Diltiazem Nifedipine Verapamil | Increased hypotension, bradycardia |
| Corticosteroids | Budesonide Fluticasone Methylprednisolone Prednisone | Increased hyperglycemia, osteoporosis, insomnia, acne |
| HIV protease inhibitors† | Atazanavir | Increased vomiting, diarrhea |
| HIV reverse transcriptase inhibitors | Tenofovir | Increased nephrotoxicity |
| Hormonal contraceptives | Ethinyl estradiol | Decreased efficacy |
| Immunosuppressants | Cyclosporine Sirolimus Tacrolimus | Increased nephrotoxicity, hypertension, neurotoxicity |
| Inhaled beta‐agonists | Salmeterol | Increased tachycardia |
| Macrolide antibiotics | Clarithromycin Erythromycin Telithromycin | Increased diarrhea, QT prolongation |
| CYP3A inducers | ||
| HIV protease inhibitors† | Atazanavir Darunavir Fosamprenavir Lopinavir | Reduced DAA levels with potentially reduced antiviral efficacy and increased drug resistance |
| HIV reverse transcriptase inhibitors | Efavirenz | |
| Narcotic analgesics | Methadone | |
| Sedatives | Zolpidem | |